Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/71097
Title: KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: Rodriguez Abreu, D.
Garassino, M. C.
Esteban, E.
Speranza, G.
Felip, E.
Domine, M.
Hochmair, M. J.
Powell, S.
Cheng, S. Y.S.
Bischoff, H. G.
Peled, N.
Hui, R.
Reck, M.
Garon, E. B.
Boyer, M.
Grossi, F.
Jennens, R.
Yang, J.
Pietanza, M. C.
Gadgeel, S.
UNESCO Clasification: 320101 Oncología
Issue Date: 2018
Journal: Annals of Oncology 
URI: http://hdl.handle.net/10553/71097
ISSN: 1569-8041
Source: Annals of Oncology [ISSN 1569-8041], v. 29
Appears in Collections:
Show full item record

Page view(s)

9
checked on Jul 4, 2020

Google ScholarTM

Check


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.